XML 21 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue:        
Total revenue $ 24,364 $ 42,888 $ 62,793 $ 67,288
Operating costs and expenses:        
Cost of goods sold $ 3,078 $ 3,076 $ 6,479 $ 4,047
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 122,567 $ 61,414 $ 197,243 $ 116,315
Selling, general and administrative 32,554 63,535 63,334 113,138
Total operating costs and expenses 158,199 128,025 267,056 233,500
Loss from operations (133,835) (85,137) (204,263) (166,212)
Interest and other, net        
Interest expense (355) (651) (856) (1,284)
Interest income and other income (expenses), net (363) 644 (817) 3,810
Total interest and other, net (718) (7) (1,673) 2,526
Loss before income taxes (134,553) (85,144) (205,936) (163,686)
Provision for (benefit from) income taxes (3) 169 130 (25)
Investment income in unconsolidated variable interest entity 562 0 323 0
Net loss $ (133,988) $ (85,313) $ (205,743) $ (163,661)
Net loss per share - basic and diluted $ (1.45) $ (0.95) $ (2.24) $ (1.84)
Weighted average number of common shares used to calculate net loss per share - basic and diluted 92,276 89,451 91,983 88,835
License Revenue [Member]        
Revenue:        
Total revenue $ 0 $ 0 $ 0 $ 0
Development and Other Revenue [Member]        
Revenue:        
Total revenue 19,641 18,957 34,228 38,402
Product Revenue, Net [Member]        
Revenue:        
Total revenue 13,371 15,693 28,733 20,648
Drug Product Revenue [Member]        
Revenue:        
Total revenue $ (8,648) $ 8,238 $ (168) $ 8,238